Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Guselkumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J looks to expand Tremfya in two pediatric indications
    J&J looks to expand Tremfya in two pediatric indications

    03 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab-302317847.html

    PR NEWSWIRE
    03 Dec 2024
    Share Share
    J & J seeks approval for first pediatric indications for Tremfya
    J & J seeks approval for first pediatric indications for Tremfya

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab-302317847.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    J&J Seeks FDA Approval for TREMFYA® in Ulcerative Colitis
    J&J Seeks FDA Approval for TREMFYA® in Ulcerative Colitis

    22 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya-guselkumab-in-ulcerative-colitis-a-first-for-an-il-23-inhibitor-302313913.html

    PR NEWSWIRE
    22 Nov 2024
    Share Share
    Tremfya is 1st IL-23 Inhibitor with Subcutaneous in Crohn's Disease
    Tremfya is 1st IL-23 Inhibitor with Subcutaneous in Crohn's Disease

    28 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-robust-results-with-a-fully-subcutaneous-regimen-in-both-induction-and-maintenance-in-crohns-disease-302288042.html

    PR NEWSWIRE
    28 Oct 2024
    Share Share
    Positive results for J&J’s Tremfya in plaque psoriasis
    Positive results for J&J’s Tremfya in plaque psoriasis

    26 Oct 2024

    // PRESS RELEASE

    https://www.jnj.com/media-center/press-releases/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-undertreated-plaque-psoriasis

    PRESS RELEASE
    26 Oct 2024
    Share Share
    J&J’s Tremfya May Set New Standard In Crohn’s Disease
    J&J’s Tremfya May Set New Standard In Crohn’s Disease

    21 Oct 2024

    // FINANCIALXPRESS

    https://www.financialexpress.com/business/healthcare-johnson-johnsons-subcutaneous-tremfya-holds-potential-to-set-new-standard-in-crohns-disease-treatment-3645772/

    FINANCIALXPRESS
    21 Oct 2024
    Share Share